(Q37183434)

18 August 2017

1 reference

title

Imatinib mesylate for the treatment of chronic myeloid leukemia (English)

1 reference

18 August 2017

main subject

chronic myeloid leukemia

0 references

1 reference

1 reference

Simona Soverini

1

0 references

Giovanni Martinelli

series ordinal

2

object named as

Giovanni Martinelli

1 reference

18 August 2017

4

Michele Baccarani

1 reference

18 August 2017

3

Ilaria Iacobucci

1 reference

18 August 2017

publication date

1 June 2008

1 reference

Expert Review of Anticancer Therapy

18 August 2017

published in

1 reference

18 August 2017

volume

8

1 reference

18 August 2017

issue

6

1 reference

18 August 2017

page(s)

853-864

1 reference

18 August 2017

cites work

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Chronic myelogenous leukemia: a review and update of therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Clinical pharmacokinetics of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Practical management of patients with chronic myeloid leukemia receiving imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Pericyte loss and microaneurysm formation in PDGF-B-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Stevens-Johnson syndrome after treatment with STI571: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Imatinib mesylate and gray hair

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Congestive heart failure is a rare event in patients receiving imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using str

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

AMN107: tightening the grip of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Lifetime Risk for Developing Congestive Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.853

21 January 2018

Identifiers

DOI

10.1586/14737140.8.6.853

1 reference

18 August 2017

1 reference